TG Therapeutics Inc (TGTX)

[stockguard]

A top momentum play
George Budwell (TG Therapeutics): Shares of the pre-revenue biotech TG Therapeutics have more than doubled in value since the start of the year, thanks to a string of positive clinical updates for its blood cancer duo of umbralisib and ublituximab.


First up, a mid-stage trial evaluating umbralisib monotherapy for marginal zone lymphoma reportedly achieved its primary endpoint of overall response rate for all treated patients. The company, in turn, hopes to turn this mid-stage success into an accelerated approval in the U.S. by next year. TG is also slated to release more top-line data from this ongoing mid-stage later this year that could lead to rapid regulatory approvals for patients with follicular lymphoma and small lymphocytic lymphoma.

The big prize, however, is the upcoming late-stage readout for the combination of umbralisib and ublituximab (or U2 for short) in patients with chronic lymphocytic leukemia (CLL). TG's goal is to demonstrate that U2 produces a superior progression-free survival rate in CLL patients, compared to those receiving a cocktail of obinutuzumab plus chlorambucil. This next major clinical catalyst should come into play by no later than mid-2020.

What does this all mean? The key item is that TG seems poised to become a commercial-stage biotech within the next 12 to 16 months and that simple fact should keep the company's stock headed in the right direction. Now, a clinical setback is always a concern with these types of companies, but TG's blood cancer pipeline has been producing some truly impressive results of late. As a result, TG's stock arguably sports a rather intriguing risk-to-reward ratio right now.

https://www.msn.com/en-us/money/topstocks/3-top-biotech-stocks-to-buy-in-april/ar-BBVJb8A